BIOLASE Stock Forecast, Price & News

+0.09 (+12.08 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume14.02 million shs
Average Volume19.64 million shs
Market Capitalization$125.63 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.



BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

370th out of 2,096 stocks

Dental Equipment & Supplies Industry

2nd out of 8 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

Is BIOLASE a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOLASE stock.
View analyst ratings for BIOLASE
or view top-rated stocks.

What stocks does MarketBeat like better than BIOLASE?

Wall Street analysts have given BIOLASE a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BIOLASE wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for BIOLASE

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings results on Thursday, May, 13th. The medical technology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical technology company earned $8.12 million during the quarter. BIOLASE had a negative net margin of 67.89% and a negative trailing twelve-month return on equity of 121.41%.
View BIOLASE's earnings history

How has BIOLASE's stock been impacted by COVID-19 (Coronavirus)?

BIOLASE's stock was trading at $0.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOL stock has increased by 44.0% and is now trading at $0.8353.
View which stocks have been most impacted by COVID-19

When did BIOLASE's stock split? How did BIOLASE's stock split work?

BIOLASE's stock reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE issued an update on its second quarter 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $7.50 million-8.50 million, compared to the consensus revenue estimate of $8.28 million.

What price target have analysts set for BIOL?

2 analysts have issued twelve-month price targets for BIOLASE's shares. Their forecasts range from $1.15 to $2.00. On average, they expect BIOLASE's share price to reach $1.58 in the next year. This suggests a possible upside of 88.6% from the stock's current price.
View analysts' price targets for BIOLASE
or view top-rated stocks among Wall Street analysts.

Who are BIOLASE's key executives?

BIOLASE's management team includes the following people:
  • Mr. John R. Beaver, Pres, CEO & Director (Age 60, Pay $309.83k)
  • Ms. Jennifer Bright, VP of Fin.
  • Mr. Matthew Wilson, VP of HR
  • Dr. Samuel B. Low, Chief Dental Officer and VP of Dental & Clinical Affairs
  • Mr. Michael C. Carroll, Corp. Sec. (Age 49)
  • Mr. David Rodriguez, Director of Education & Events

What is Todd Norbe's approval rating as BIOLASE's CEO?

8 employees have rated BIOLASE CEO Todd Norbe on Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Todd Norbe in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BIOLASE's key competitors?

What other stocks do shareholders of BIOLASE own?

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.38%), Renaissance Technologies LLC (1.48%), Perkins Capital Management Inc. (1.10%), Geode Capital Management LLC (0.79%), Citadel Advisors LLC (0.26%) and Northern Trust Corp (0.18%). Company insiders that own BIOLASE stock include Jack W Schuler, John R Beaver and Larry N Feinberg.
View institutional ownership trends for BIOLASE

Which institutional investors are buying BIOLASE stock?

BIOL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Perkins Capital Management Inc., Citadel Advisors LLC, Millennium Management LLC, Northern Trust Corp, and Goldman Sachs Group Inc.. Company insiders that have bought BIOLASE stock in the last two years include John R Beaver, and Larry N Feinberg.
View insider buying and selling activity for BIOLASE
or or view top insider-buying stocks.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.84.

How much money does BIOLASE make?

BIOLASE has a market capitalization of $125.63 million and generates $22.78 million in revenue each year. The medical technology company earns $-16,830,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does BIOLASE have?

BIOLASE employs 135 workers across the globe.

What is BIOLASE's official website?

The official website for BIOLASE is

Where are BIOLASE's headquarters?

BIOLASE is headquartered at 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.